Compare APEI & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | OBX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 875.2M | 861.1M |
| IPO Year | 2007 | 2026 |
| Metric | APEI | OBX |
|---|---|---|
| Price | $48.69 | $13.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $62.83 | $39.00 |
| AVG Volume (30 Days) | 200.1K | ★ 341.9K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.27 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $198,174,000.00 | N/A |
| Revenue This Year | $6.88 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | $33.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.20 | $11.52 |
| 52 Week High | $61.59 | $39.00 |
| Indicator | APEI | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 47.17 |
| Support Level | $46.79 | $11.84 |
| Resistance Level | $59.32 | $18.21 |
| Average True Range (ATR) | 1.30 | 1.06 |
| MACD | 0.21 | 0.42 |
| Stochastic Oscillator | 73.08 | 77.60 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator, provides online postsecondary education as a distance-learning, graduate-level institution for military officers seeking a degree in military studies; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.